009420.KO Hanall Biopharma

Healthcare Pharmaceuticals Korea Stock Exchange
39,450 KRW
Close of Nov 5, 2026
35,100 73,000
Market cap
KRW 2.01T
P/E
-
P/B
11.69x
ROE
-23.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 009420.KO undervalued?

Graham number

The Graham number of Hanall Biopharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hanall Biopharma fundamental analysis

No fundamental analysis for Hanall Biopharma yet.

Hanall Biopharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, …

Full company profile